Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT1 | Q99873 | 1/20 | 0.59 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.55 |
| ▸ | PLA2G2A | P14555 | 2/20 | 0.54 |
| ▸ | EPHX2 | P34913 | 5/20 | 0.50 |
| ▸ | PLA2G4A | P47712 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11127968 | 0.83 | PRMT1 (0.74) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL2808479 | 0.83 | PRMT1 (0.74) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL16285212 | 0.83 | PAOX (0.46) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL18122755 | 0.81 | PRMT1 (0.55) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL1333097 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL1173562 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL907297 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL21099597 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL907518 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A | |
| SCHEMBL1173957 | 0.81 | ADRA1A (0.66) | PRMT1ADRA1APLA2G2AEPHX2PLA2G4A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. | 2023-04-06 | — | — | US | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | Magenta Therapeutics, Inc. (US) | 2022-01-25 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SENSEI BIOTHERAPEUTICS, INC. | 2016-12-22 | — | — | US | disclosed |
| WO-2014197854-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
| WO-2014197854-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | IGENICA BIOTHERAPEUTICS, INC. (US) | 2014-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230109312-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | PRMT1 3232/4885ADRA1A 4668/4885PLA2G2A 1095/4885 |
| US-11229711-B2 | Linkers for antibody-drug conjugates and related compounds, compositions, and methods of use | CLSPN, SDCBP, DCLRE1A | PRMT1 3374/4885ADRA1A 4651/4885PLA2G2A 1491/4885 |
| US-20160367699-A1 | NOVEL LINKERS FOR ANTIBODY-DRUG CONJUGATES AND RELATED COMPOUNDS, COMPOSITIONS, AND METHODS OF USE | SDCBP, DCLRE1A, BCR | PRMT1 3232/4885ADRA1A 4668/4885PLA2G2A 1095/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.